Brain Cancer Clinical Trials

Showing 501-520 of 1,466 trials

Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study

NCT04047602

This study will evaluate the rate of radiation necrosis following treatment with immune checkpoint inhibitor (ICI) treatment and radiation therapy in subjects with metastatic brain cancer. Subjects will be treated with the standard of care immunotherapy followed by radiation therapy via stereotactic radiosurgery at a reduced dose.

Brain TumorBrain MetastasesBrain Cancer

Indiana University18 participantsStarted Dec 2019

Indianapolis, Indiana, United States • Indianapolis, Indiana, United States • Portland, Oregon, United States

Active Not RecruitingPhase 1/2

AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

NCT04881032

This is a phase I/II clinical trial evaluating the association of AGuIX nanoparticles with radiotherapy plus concomitant Temozolomide in the treatment of newly diagnosed glioblastoma. The primary objectives of this study were to determine the recommended dose of AGuIX in combination with radiotherapy and TMZ during the concomitant radiochemotherapy period (phase I) and to estimate the efficacy of the combination radiochemotherapy + AGuIX (recommended dose), measured by the 6-month progression-free survival rate (PFS) (phase II) Three dose levels of intravenous AGuIX nanoparticles will be explored: 50 mg/kg, 75 mg/kg and 100 mg/kg.

Glioblastoma

Centre Jean Perrin66 participantsStarted Mar 2022

Brest, France • Clermont-Ferrand, France • Grenoble, France +6 more locations

Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study

AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

Related Searches

PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas

A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma

Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases

STRatifying Adult DIffuse Lower-grade Gliomas Based on Their VARIed Metabolic Profiles (STRADIVARI Project)

Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)

18F-DOPA-PET in Planning Surgery in Patients With Gliomas

Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery

18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

Drug Response Testing and Repurposing Using Glioblastoma Organoid

A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma

Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma

Feasibility of the LUM Imaging System for Detection of Cancer to the Brain

A Phase 2 Study of HX301 in Patients with High-grade Giloma